Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

Donato Rigante, Sergio Davì, Francesca Minoia, Angela Pistorio, Annacarin Horne, Alessandro Consolaro, Silvia Rosina, Francesca Bovis, Rolando Cimaz, Maria Luz Gamir, Norman T. Ilowite, Isabelle Kone-Paut, Sheila Knupp Feitosa De Oliveira, Deborah Mccurdy, Clovis Artur Silva, Flavio Sztajnbok, Elena Tsitsami, Erbil Unsal, Jennifer E. Weiss, Nico WulffraatMario Abinun, Amita Aggarwal, Maria Teresa Apaz, Itziar Astigarraga, Fabrizia Corona, Ruben Cuttica, Gianfranco D'Angelo, Eli M. Eisenstein, Soad Hashad, Loredana Lepore, Velma Mulaosmanovic, Susan Nielsen, Sampath Prahalad, Valda Stanevicha, Gary Sterba, Gordana Susic, Syuji Takei, Ralf Trauzeddel, Mabruka Zletni, Nicolino Ruperto, Alberto Martini, Randy Q. Cron, Angelo Ravelli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

67 Citazioni (Scopus)

Abstract

OBJECTIVE: To compare the capacity of the 2004 diagnostic guidelines for hemophagocytic lymphohistiocytosis (HLH-2004) with the capacity of the preliminary diagnostic guidelines for systemic juvenile idiopathic arthritis (JIA)-associated macrophage activation syndrome (MAS) to discriminate MAS complicating systemic JIA from 2 potentially confusable conditions, represented by active systemic JIA without MAS and systemic infection. METHODS: International pediatric rheumatologists and hemato-oncologists were asked to retrospectively collect clinical information from patients with systemic JIA-associated MAS and confusable conditions. The ability of the guidelines to differentiate MAS from the control diseases was evaluated by calculating the sensitivity and specificity of each set of guidelines and the kappa statistics for concordance with the physician's diagnosis. Owing to the fact that not all patients were assessed for hemophagocytosis on bone marrow aspirates and given the lack of data on natural killer cell activity and soluble CD25 levels, the HLH-2004 guidelines were adapted to enable the diagnosis of MAS when 3 of 5 of the remaining items (3/5-adapted) or 4 of 5 of the remaining items (4/5-adapted) were present. RESULTS: The study sample included 362 patients with systemic JIA and MAS, 404 patients with active systemic JIA without MAS, and 345 patients with systemic infection. The best capacity to differentiate MAS from systemic JIA without MAS was found when the preliminary MAS guidelines were applied. The 3/5-adapted HLH-2004 guidelines performed better than the 4/5-adapted guidelines in distinguishing MAS from active systemic JIA without MAS. The 3/5-adapted HLH-2004 guidelines and the preliminary MAS guidelines with the addition of ferritin levels ≥500 ng/ml discriminated best between MAS and systemic infections. CONCLUSION: The preliminary MAS guidelines showed the strongest ability to identify MAS in systemic JIA. The addition of hyperferritinemia enhanced their capacity to differentiate MAS from systemic infections. The HLH-2004 guidelines are likely not appropriate for identification of MAS in children with systemic JIA.
Lingua originaleEnglish
pagine (da-a)2871-2880
Numero di pagine10
RivistaARTHRITIS & RHEUMATOLOGY
Volume2014; 66(10)
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Juvenile idiopathic arthritis
  • Macrophage activation syndrome

Fingerprint Entra nei temi di ricerca di 'Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis'. Insieme formano una fingerprint unica.

Cita questo